What metrics would you use to evaluate MSD's RotaTeq rotavirus vaccine?

Introduction

Evaluating the success of MSD's RotaTeq rotavirus vaccine requires a comprehensive approach to product metrics. This vaccine, designed to prevent rotavirus gastroenteritis in infants, plays a crucial role in global health initiatives. To assess its performance effectively, we'll follow a structured framework covering core metrics, supporting indicators, and risk factors while considering all key stakeholders.

Step 1

Product Context

RotaTeq is an oral pentavalent rotavirus vaccine developed by Merck Sharp & Dohme (MSD) to prevent rotavirus gastroenteritis in infants. Key stakeholders include:

1. Infants and their parents/caregivers (end-users)
2. Healthcare providers (administering the vaccine)
3. Public health organizations (recommending and distributing the vaccine)
4. MSD (manufacturer)
5. Regulatory bodies (ensuring safety and efficacy)

The user flow involves healthcare providers administering the vaccine orally to infants in three doses, typically at 2, 4, and 6 months of age. Parents bring their children for routine vaccinations, where RotaTeq is administered alongside other recommended vaccines.

RotaTeq fits into MSD's broader strategy of developing innovative vaccines to address global health challenges. It competes with GlaxoSmithKline's Rotarix, another rotavirus vaccine, but RotaTeq's pentavalent formulation targets a broader range of rotavirus strains.

In terms of product lifecycle, RotaTeq is in the maturity stage, having been on the market since 2006. It has established a strong presence in developed markets and is expanding in developing countries through partnerships with organizations like GAVI.

Physical Product Considerations:

• Distribution channels: Primarily through healthcare systems and vaccination programs
• Shelf-life: Requires proper cold chain management
• Sales model: Bulk purchases by governments and health organizations, as well as individual sales through healthcare providers